Zacks Research Issues Pessimistic Outlook for Amgen Earnings

Amgen Inc. (NASDAQ:AMGN) – Zacks Research lowered their Q1 2025 EPS estimates for shares of Amgen in a report issued on Wednesday, December 4th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $4.56 for the quarter, down from their previous forecast of $4.57. The consensus estimate for Amgen’s current full-year earnings is $19.51 per share. Zacks Research also issued estimates for Amgen’s Q4 2025 earnings at $5.25 EPS, FY2025 earnings at $20.04 EPS, Q1 2026 earnings at $4.67 EPS, Q2 2026 earnings at $5.13 EPS and FY2026 earnings at $20.66 EPS.

Other equities research analysts have also recently issued reports about the stock. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Robert W. Baird restated an “underperform” rating and issued a $215.00 price target on shares of Amgen in a report on Wednesday, September 25th. Jefferies Financial Group restated a “buy” rating and issued a $380.00 price target on shares of Amgen in a report on Tuesday, November 12th. Citigroup cut their price target on shares of Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. Finally, William Blair restated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $323.05.

Amgen Price Performance

AMGN opened at $272.58 on Friday. The company’s 50 day simple moving average is $306.58 and its 200 day simple moving average is $315.82. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen has a 1 year low of $257.80 and a 1 year high of $346.85. The stock has a market capitalization of $146.52 billion, a PE ratio of 34.90, a P/E/G ratio of 3.08 and a beta of 0.55.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. During the same period last year, the company earned $4.96 earnings per share. The company’s quarterly revenue was up 23.2% on a year-over-year basis.

Hedge Funds Weigh In On Amgen

Hedge funds have recently added to or reduced their stakes in the business. Capital Performance Advisors LLP acquired a new position in Amgen in the third quarter worth $25,000. Strategic Financial Concepts LLC acquired a new position in Amgen in the second quarter worth $26,000. Legacy Investment Solutions LLC acquired a new position in Amgen in the third quarter worth $29,000. Hershey Financial Advisers LLC acquired a new position in Amgen in the second quarter worth $30,000. Finally, nVerses Capital LLC acquired a new position in Amgen in the second quarter worth $31,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be paid a $2.25 dividend. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.30%. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.